CEO succession is routine and non-material for stock performance. Monitor any strategic shifts or pipeline updates under Severino's leadership, particularly in Duchenne programs and siRNA pipeline. The orderly transition (Ingram advising through year-end) reduces execution risk.
Price Chart
Executive Summary
Sarepta Therapeutics appointed Michael Severino, M.D., as CEO effective July 28, 2026, succeeding Doug Ingram who is retiring and will serve as a consultant through December 31, 2026. Severino brings extensive R&D and leadership experience from AbbVie and Tessera Therapeutics, and will receive a compensation package including a $1.18M base salary, 110% target bonus, and a $35M sign-on equity grant.
Key Facts
- Michael Severino appointed CEO and Class I director effective July 28, 2026
- Douglas Ingram retires as CEO and board member, enters consulting agreement at $15,000/month through Dec 31, 2026
- Severino's base salary: $1,180,000 per year; target bonus: 110% of base salary
- Sign-on equity grant: ~$35,000,000 in RSUs and premium-priced stock options vesting over 4 years
- Severino previously served as CEO of Tessera Therapeutics and Vice Chairman/President at AbbVie
Financial Impact
CEO compensation: $1,180,000 base salary, ~$35,000,000 sign-on equity grant; outgoing CEO consulting fee: $15,000/month
Risk Factors
- Execution risk during leadership transition
- Potential strategic pivot away from current Duchenne-focused strategy
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (SRPT) — Batch item 1 | 0001193125-26-316995 |
| Document: d101719d8k.htm | 0001193125-26-316995 |
| Document: d101719dex102.htm | 0001193125-26-316995 |
| Document: d101719dex991.htm | 0001193125-26-316995 |
| Document: 0001193125-26-316995-index-headers.html | 0001193125-26-316995 |
| Document: 0001193125-26-316995-index.html | 0001193125-26-316995 |
| Document: 0001193125-26-316995.txt | 0001193125-26-316995 |
| 8-K Filing (SRPT) — Batch item 8 | 0001193125-26-316995 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 27, 2026 9w ago | 8-K | $15.89 $18.13 | ▲ +14.10% | ▲ +10.80% | $17.50 (+10.13%) |
Jun 11, 2026 16w ago | Institutional Cluster | $15.00 $20.52 | ▲ +36.80% | ▲ +34.91% | $17.50 (+16.67%) |
Jun 4, 2026 17w ago | 8-K | $15.75 $19.18 | ▲ +21.78% | ▲ +19.92% | $17.50 (+11.11%) |
Apr 24, 2026 22w ago | DEFA14A | $20.89 $16.67 | ▼ −20.18% | ▼ −25.14% | $17.50 (−16.21%) |
Feb 25, 2026 31w ago | 8-K | $18.85 $23.75 | ▲ +26.00% | ▲ +31.24% | $17.50 (−7.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access